Antipsychotic Polypharmacy: Prevalence, Background and Consequences
The primary purpose of the study is to investigate whether an intensive educational intervention can reduce the use of antipsychotic polypharmacy. It is hypothesised that the use of antipsychotic polypharmacy is, in some degree, dependent on non-patient related factors.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Health Services Research
|Official Title:||Antipsychotic Polypharmacy: Prevalence, Background and Consequences|
- Prevalence of antipsychotic polypharmacy [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- Questionnaire assessment of non-patient related factors. Medical records data. Cost-effectiveness analysis. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
|Study Start Date:||January 2008|
|Study Completion Date:||October 2009|
|Primary Completion Date:||January 2009 (Final data collection date for primary outcome measure)|
Behavioral: Implementation of guideline
Outreach visits with interactive education for health staff
|No Intervention: B|
Several surveys have shown a high prevalence of antipsychotic polypharmacy (concomitant prescription of at least 2 different antipsychotics) among patients with schizophrenia even though international guidelines recommend monotherapy.
From register data areas with differences in the prevalence of antipsychotic polypharmacy will be identified. Two high prevalence areas will be randomized to either control or intervention area. In the intervention area an intensive educational intervention consisting of outreach visits with a multifaceted approach will be carried out with the duration of 1 year.
Differences in health staff related factors such as knowledge and attitude towards clinical guidelines will be assessed with a questionnaire before and after the intervention in the intervention area as well as in the low prevalence area at baseline.
Medical records data describing the use of antipsychotic polypharmacy will be collected. With register data health economic issues will be assessed.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00541398
|Glostrup, Denmark, 2600|
|Study Director:||Birte Glenthøj, Professor||University of Copenhagen|